

A randomised controlled trial of mobile phones to influence adherence to first line antiretroviral treatment among human immunodeficiency virus (HIV) infected patients in South India

Submission date 18/05/2009	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
Registration date 24/07/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 07/10/2016	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Ayesha Mariette De Costa

Contact details
Dept. Of Public Health Sciences
Karolinska Institutet
Stockholm
Sweden
SE 171 77

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title

The antiretroviral roll out for human immunodeficiency virus (HIV) in India (HIVIND) - strengthening capacity to promote adherence and patient follow-up in the context: a two-centre, randomised, controlled, open trial in South India to study an innovative approach using mobile phones delivery to promote adherence in antiretroviral naive, HIV+ Indian patients

Acronym

HIVIND

Study objectives

Antiretroviral treatment (ART) naive patients started on ART, followed up for 24 months after ART initiation, and receiving reminders on their mobile telephones will have better adherence and hence, a longer time to resistance development than patients who do not receive such reminders over the same period.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Sweden: Karolinska Institutet, Stockholm, 18/03/2009, ref: 2009/303 - 31/2
2. Finland: University of Tampere, 21/04/2009, ref: R09064
3. India: St. John's National Academy of Health, Bangalore, 20/03/2009, ref: IERB/1/172/09
4. India: YRG Care, Chennai, 18/04/2009
5. Vietnam: Hanoi Medical University, 02/02/2009, ref: 66/HMURB

Study design

Two-centre randomised controlled open trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Human immunodeficiency virus (HIV)

Interventions

Both arms will receive mobile telephones. However in the control arm, there will be no further interaction via the mobile phone. In the intervention arm, the mobile phone intervention will be as described below:

1. Each of the 300 patients in the intervention arm will receive a cell phone (handset) with free incoming calls, and a set amount of talk time per month which will be prepaid by the project (approximately Rs 200 per phone per month). The talk time is included to allow functionality of the phone, and expiry of the talk time will not disallow any of the project related communications (this has been discussed with the mobile network company).
- 2.1. Automated voice calls (IVR) reminding patients to take their medication will go out once a week at a specified time to each of the 150 patients in the intervention arm at each site. This will be in Kannada, Telugu or Tamil, depending on the language the patient speaks. If the patient for any reason does not receive this call, then a repeat call is sent within the next hour.
- 2.2. A second weekly 'adherence reminder contact' will be made by hospital counsellors, from a

number based at the hospital and dedicated to this purpose, to remind the patients about his medication (a standard script for this part of the conversation), enquire about the patients' wellbeing, follow up on any pending issues. (These calls will be scheduled on the 4th day after the IVR has been sent out).

3. Patients will report back once a day to record that they have taken their medication. A simple functionality for this has been developed involving two clicks of the phone.

In the event of non-receipt of such a message or a negative response, an automatic reminder will be sent to the patient 24 hours later.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Time to occurrence of virological failure (defined as having greater than 400 copies/ml on two consecutive measures at least one month apart. Date of failure is documented as the date of initial reading of the value greater than 400 copies/ml.

Key secondary outcome(s)

Self-reported adherence expressed as a percentage

Completion date

31/12/2012

Eligibility

Key inclusion criteria

1. Human immunodeficiency virus (HIV) seropositive
2. Aged between 18 - 60 years, either sex
3. Meet criteria to start ART (in India, ART is indicated for symptomatic patients with a World Health Organization [WHO] Clinical Stage 4 condition regardless of CD4 counts and plasma viral load; WHO Stage 3 condition with CD4 less than 350/mm³ and in asymptomatic patients, with CD4 count less than 200/mm³)
4. ART naive (i.e. no prior antiretroviral therapy or ART for less than 7 days)
5. Residence in the Southern Indian States with the ability to visit clinic regularly for follow-up visits

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Severely ill (Karnofsky score less than 70) at the time of recruitment
2. Impaired renal function (creatinine greater than 2 times upper limit of normal)
3. Study participant already recruited in the same household
4. Non-availability of mobile telephone network

Date of first enrolment

01/09/2009

Date of final enrolment

31/12/2012

Locations

Countries of recruitment

India

Sweden

Study participating centre

Karolinska Institutet

Stockholm

Sweden

SE 171 77

Sponsor information

Organisation

European Union (EU) (Belgium)

ROR

<https://ror.org/019w4f821>

Funder(s)

Funder type

Government

Funder Name

Seventh Framework Programme

Alternative Name(s)

EC Seventh Framework Programme, European Commission Seventh Framework Programme, EU Seventh Framework Programme, European Union Seventh Framework Programme, FP7

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	10/03/2014		Yes	No
Results article	results	24/10/2014		Yes	No
Results article	results	02/11/2015		Yes	No
Results article	results	27/01/2016		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes